Retosiban
- Generic Name
- Retosiban
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H34N4O5
- CAS Number
- 820957-38-8
- Unique Ingredient Identifier
- GIE06H28OX
- Background
Retosiban has been used in trials studying the treatment of Premature Labor and Obstetric Labour, Premature.
- Associated Conditions
- -
- Associated Therapies
- -
Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 98
- Registration Number
- NCT02292784
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT02292771
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT01867996
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath